Cytokinetics, Inc. reported that its Phase 3 ACACIA‑HCM trial met both dual primary endpoints for aficamten in patients with symptomatic non‑obstructive hypertrophic cardiomyopathy (nHCM). The study, which enrolled 516 participants, showed statistically significant improvements from baseline to week 36 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ‑CSS) and in maximal exercise performance (pVO₂).
Secondary outcomes also favored aficamten, with meaningful gains in New York Heart Association functional class, a composite ventilatory efficiency and pVO₂ z‑score, and reductions in NT‑proBNP levels. Safety data were reassuring; no new safety signals emerged, and the proportion of participants who completed the planned dosing schedule was similar between aficamten (88.4 %) and placebo (90.3 %). Two participants experienced a serious adverse event of heart failure with left‑ventricular ejection fraction < 50 %, and 3 % of aficamten recipients had treatment interruptions due to LVEF < 40 %, consistent with the boxed warning for aficamten.
The trial’s success marks the first time a cardiac myosin inhibitor has demonstrated statistically significant improvements in exercise capacity and symptom burden in nHCM, a patient population that has historically lacked effective therapies. By expanding aficamten’s potential indication beyond obstructive HCM, Cytokinetics positions itself to capture a larger addressable market and to differentiate itself from competitors such as Bristol Myers Squibb’s mavacamten, which failed to show benefit in the ODYSSEY‑HCM trial for nHCM.
Dr. Fady Malik, Cytokinetics’ executive vice president of R&D, said, "ACACIA‑HCM…is the first clinical trial to demonstrate statistically significant improvements in exercise capacity and symptom burden in patients with non‑obstructive HCM. We believe that the totality and consistency of evidence…across multiple patient‑reported and physician‑assessed endpoints of symptom improvement and physical function are clinically meaningful for patients with non‑obstructive HCM." He added, "We are grateful to the clinical trial investigators and staff, as well as the patients who participated in this trial. We look forward to presenting the results from ACACIA‑HCM at an upcoming medical meeting, as well as discussing them with the U.S. FDA and other regulatory authorities."
Investors reacted positively to the announcement, with analysts raising expectations for aficamten’s commercial prospects in nHCM. The trial’s dual‑endpoint success de‑risks the drug’s development path and supports a broader regulatory strategy that could lead to approval for the larger nHCM market.
Cytokinetics plans to present the full data set at an upcoming medical meeting and to engage the U.S. FDA and other regulatory bodies in discussions about a potential new indication. The company’s prior regulatory milestone—approval of MYQORZO (aficamten) for obstructive HCM on December 19, 2025—provides a foundation for pursuing the nHCM indication.
While the company reported a net loss of $183 million, or $(1.50) per share, in its most recent quarter, the ACACIA‑HCM results offer a significant upside to the company’s long‑term revenue potential and may help offset the current financial headwinds as aficamten moves closer to market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.